CN109195994A - 针对cd137的新型双特异性多肽 - Google Patents

针对cd137的新型双特异性多肽 Download PDF

Info

Publication number
CN109195994A
CN109195994A CN201780025116.2A CN201780025116A CN109195994A CN 109195994 A CN109195994 A CN 109195994A CN 201780025116 A CN201780025116 A CN 201780025116A CN 109195994 A CN109195994 A CN 109195994A
Authority
CN
China
Prior art keywords
seq
antibody
heavy chain
light chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780025116.2A
Other languages
English (en)
Chinese (zh)
Inventor
E·达伦
P·埃尔马克
C·富尔宾
P·诺林
A·萨尔
L·V·尚茨
N·韦通迈基
J·彼得森
L·瓦拉斯
S·弗里策尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alligator Bioscience AB
Original Assignee
Alligator Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience AB filed Critical Alligator Bioscience AB
Publication of CN109195994A publication Critical patent/CN109195994A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
CN201780025116.2A 2016-04-22 2017-04-24 针对cd137的新型双特异性多肽 Pending CN109195994A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1607046.8 2016-04-22
GB201607046 2016-04-22
PCT/EP2017/059656 WO2017182672A1 (en) 2016-04-22 2017-04-24 Novel bispecific polypeptides against cd137

Publications (1)

Publication Number Publication Date
CN109195994A true CN109195994A (zh) 2019-01-11

Family

ID=58609424

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780025116.2A Pending CN109195994A (zh) 2016-04-22 2017-04-24 针对cd137的新型双特异性多肽

Country Status (14)

Country Link
US (2) US20190169308A1 (enExample)
EP (1) EP3445788B1 (enExample)
JP (2) JP2019523630A (enExample)
KR (1) KR102426765B1 (enExample)
CN (1) CN109195994A (enExample)
AU (1) AU2017252233A1 (enExample)
BR (1) BR112018071612A2 (enExample)
CA (1) CA3021618A1 (enExample)
DK (1) DK3445788T3 (enExample)
ES (1) ES2910365T3 (enExample)
IL (1) IL262482A (enExample)
MX (1) MX2018012897A (enExample)
RU (1) RU2018139339A (enExample)
WO (1) WO2017182672A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112592404A (zh) * 2019-09-20 2021-04-02 上海交通大学医学院 抗体活性改造及其筛选方法
CN113330036A (zh) * 2019-01-25 2021-08-31 信达生物制药(苏州)有限公司 结合pd-l1和ox40的双特异性抗体
WO2024061364A1 (zh) * 2022-09-22 2024-03-28 成都盛世君联生物技术有限公司 一种抗4-1bb纳米抗体及其制备和应用

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017008575B1 (pt) 2014-10-29 2021-07-13 Bicyclerd Limited Ligantes de peptídeos bicíclicos específicos a mt1-mmp, conjugado de fármaco, processo para preparação de um conjugado de fármaco e composição farmacêutica
CA3025345A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
CN109563171B (zh) 2016-06-20 2023-09-19 F-星治疗有限公司 结合pd-l1和lag-3的结合分子
MX2018015853A (es) 2016-07-14 2019-08-21 Genmab As Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP4342912A3 (en) 2016-09-23 2024-05-22 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
KR20240165484A (ko) 2017-04-11 2024-11-22 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
WO2019016402A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO
CN118772242A (zh) 2017-08-04 2024-10-15 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
AU2018309339C1 (en) 2017-08-04 2025-08-21 BioNTech SE Binding agents binding to PD-L1 and CD137 and use thereof
EP3710477A1 (en) 2017-11-13 2020-09-23 Crescendo Biologics Limited Single domain antibodies that bind to cd137
JP7489316B2 (ja) 2017-12-19 2024-05-23 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CN109970865B (zh) * 2017-12-28 2022-10-04 上海细胞治疗研究院 一种cd137双向激活共刺激分子受体及其用途
BR112020014576A2 (pt) 2018-02-23 2020-12-08 Bicycletx Limited Ligantes peptídicos bicíclicos multiméricos
SG11202008399QA (en) * 2018-03-12 2020-09-29 Genmab As Antibodies
SG11202009773VA (en) * 2018-04-04 2020-10-29 Bicycletx Ltd Heterotandem bicyclic peptide complexes
EP3773913A1 (en) 2018-04-11 2021-02-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
US12168691B2 (en) 2018-05-31 2024-12-17 Board Of Regents, The University Of Texas System VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
WO2019234187A1 (en) * 2018-06-06 2019-12-12 Leadartis, S.L. Trimeric polypeptide complexes and uses thereof
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
TWI861005B (zh) 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 結合pd-l1及cd137的抗體分子
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
IL280002B2 (en) 2018-07-12 2025-05-01 F Star Beta Ltd Antibody molecules that bind CD137 and OX40
US12195533B2 (en) 2018-07-24 2025-01-14 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
JP7596263B2 (ja) * 2018-10-10 2024-12-09 ザイムワークス ビーシー インコーポレイテッド ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
TWI863932B (zh) * 2018-10-11 2024-12-01 美商因荷布瑞克斯生物科學公司 5t4單域抗體及其治療性組合物
CN112638950B (zh) * 2018-10-22 2024-09-06 南通壹宸生物医药科技有限公司 一种双特异性抗体
US12195538B2 (en) * 2018-11-30 2025-01-14 Abl Bio Inc. Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
CN113677703A (zh) * 2018-12-17 2021-11-19 鳄鱼生物科学公司 多肽
CN113677710A (zh) * 2018-12-17 2021-11-19 鳄鱼生物科学公司 多肽
GB201820556D0 (en) * 2018-12-17 2019-01-30 Alligator Bioscience Ab Novel polypeptides
CN113474045A (zh) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 Pd-l1特异性的双环肽配体
US20220008570A1 (en) * 2018-12-21 2022-01-13 Actinium Pharmaceuticals, Inc. Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
GB201905100D0 (en) * 2019-04-10 2019-05-22 Antibody Innovation Ltd Polypeptides and methods of use
JP2022532134A (ja) 2019-05-09 2022-07-13 バイスクルテクス・リミテッド Ｏｘ４０に特異的な二環式ペプチドリガンド
CA3147420A1 (en) * 2019-07-26 2021-02-04 Abl Bio Inc. Anti-egfr/anti-4-1bb bispecific antibody and use thereof
WO2021020846A1 (en) 2019-07-26 2021-02-04 Abl Bio Inc. Anti-her2/anti-4-1bb bispecific antibody and use thereof
TWI862640B (zh) * 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
DK4464721T3 (da) * 2019-10-03 2025-07-21 Bicycletx Ltd Bicykliske heterotandem-peptidkomplekser
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
WO2021101346A1 (en) * 2019-11-21 2021-05-27 Dong-A St Co., Ltd. Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof
WO2021137230A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells and uses of same
US20230048719A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
US11396647B2 (en) 2020-01-07 2022-07-26 Board Of Regents, The University Of Texas System Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
KR20220148228A (ko) * 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
KR20220145859A (ko) * 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
WO2021207827A1 (en) * 2020-04-15 2021-10-21 Zymeworks Inc. Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
EP4155319A4 (en) * 2020-06-30 2024-06-12 Nona Biosciences (Suzhou) Co., Ltd. 4-1BB BINDING PROTEIN AND ITS USE
US12122845B2 (en) 2020-08-07 2024-10-22 Eutilex Co., Ltd. Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof
AU2021374803A1 (en) * 2020-11-03 2023-06-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
US20240084025A1 (en) * 2021-01-25 2024-03-14 Yuhan Corporation Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody
WO2023034564A2 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-cd33 antibodies and uses thereof
WO2023061421A1 (en) * 2021-10-12 2023-04-20 Concept To Medicine Biotech Co., Ltd. Single-domain 4-1bb antibodies
WO2023174521A1 (en) * 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
CN120152994A (zh) * 2022-09-06 2025-06-13 天境生物科技(上海)有限公司 多特异性构建体及其用途
WO2024085166A1 (ja) * 2022-10-19 2024-04-25 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
WO2024117781A1 (ko) * 2022-11-29 2024-06-06 (주) 테라베스트 Cd137 세포외 도메인을 포함하는 융합단백질, 이를 발현하는 면역세포 및 이의 용도
WO2024143643A1 (ko) * 2022-12-30 2024-07-04 앱클론(주) Cd137에 특이적으로 결합하는 어피바디 및 이의 용도
WO2025035107A2 (en) * 2023-08-09 2025-02-13 Curadh Mtr, Inc. Trophoblast glycoprotein antibody compositions and methods of use
WO2025056180A1 (en) * 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103347898A (zh) * 2011-01-10 2013-10-09 Ct大西洋有限公司 包括与肿瘤相关抗原结合抗体的联合治疗
WO2015156268A1 (ja) * 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
EP2161286A1 (en) * 1999-11-18 2010-03-10 Oxford Biomedica (UK) Limited Antibodies
EP1975182A1 (en) * 2000-02-01 2008-10-01 PanGenetics B.V. CD40-binding APC-activating molecules
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
RU2007108716A (ru) 2004-09-10 2008-10-20 Вайет (Us) Гуманизированные антитела к антигену 5т4 и конъюгаты гуманизированного антитела к антигену 5т4 с калихеамицином
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SI2691417T2 (sl) 2011-03-29 2025-05-30 Roche Glycart Ag FC variante protitelesa
KR101681818B1 (ko) 2011-08-23 2016-12-01 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
MX2014003313A (es) * 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
CN112546231A (zh) * 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN117843799A (zh) * 2015-01-08 2024-04-09 生物技术公司 激动性tnf受体结合剂
AU2016206707A1 (en) * 2015-01-14 2017-08-10 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CN107709367A (zh) * 2015-05-21 2018-02-16 鳄鱼生物科学公司 新型多肽
BR112019017628A2 (pt) * 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
WO2019016402A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103347898A (zh) * 2011-01-10 2013-10-09 Ct大西洋有限公司 包括与肿瘤相关抗原结合抗体的联合治疗
WO2015156268A1 (ja) * 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C ARNDT，ET AL.: "Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33:description of a novel modular targeting system", 《LEUKEMIA》 *
李加涛等: "CD137分子及其肿瘤免疫治疗近况", 《国际免疫学杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113330036A (zh) * 2019-01-25 2021-08-31 信达生物制药(苏州)有限公司 结合pd-l1和ox40的双特异性抗体
CN112592404A (zh) * 2019-09-20 2021-04-02 上海交通大学医学院 抗体活性改造及其筛选方法
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
WO2024061364A1 (zh) * 2022-09-22 2024-03-28 成都盛世君联生物技术有限公司 一种抗4-1bb纳米抗体及其制备和应用

Also Published As

Publication number Publication date
EP3445788B1 (en) 2022-01-19
IL262482A (en) 2018-12-31
US12173082B2 (en) 2024-12-24
US20220213213A1 (en) 2022-07-07
RU2018139339A3 (enExample) 2020-09-28
AU2017252233A1 (en) 2018-11-15
JP2019523630A (ja) 2019-08-29
JP2022058338A (ja) 2022-04-12
KR102426765B1 (ko) 2022-07-29
MX2018012897A (es) 2019-01-17
WO2017182672A1 (en) 2017-10-26
KR20180135454A (ko) 2018-12-20
US20190169308A1 (en) 2019-06-06
ES2910365T3 (es) 2022-05-12
EP3445788A1 (en) 2019-02-27
BR112018071612A2 (pt) 2019-02-19
CA3021618A1 (en) 2017-10-26
DK3445788T3 (en) 2022-04-11
RU2018139339A (ru) 2020-05-22

Similar Documents

Publication Publication Date Title
CN109195994A (zh) 针对cd137的新型双特异性多肽
CN103458930B (zh) 针对cd74的人抗体和抗体-药物缀合物
JP7489316B2 (ja) Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
JP2021097674A (ja) Ｔｎｆファミリーリガンド三量体を含む抗原結合分子
TWI609887B (zh) 新穎的抗原結合蛋白及其作爲治療癌症之定址產物的用途
CN118546959A (zh) Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
TW202005984A (zh) 結合pd-l1及cd137的抗體分子
US20120251554A1 (en) Anti-cd33 antibodies and use thereof for immunotargeting in treating cd33-associated illnesses
CN110545845A (zh) 抗cd33抗体药剂
US20190161555A1 (en) Bispecific Antibodies Directed Against OX40 and a Tumor-Associated Antigen
CN111094346A (zh) 用于肿瘤特异性细胞消耗的化合物和方法
US20230272110A1 (en) Antibodies that bind psma and gamma-delta t cell receptors
US20220073635A1 (en) Novel polypeptides
ES3040993T3 (en) Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
JP2023518189A (ja) デルタ鎖媒介性免疫を調節するための材料及び方法
JP2023548522A (ja) 免疫チェックポイント阻害剤と抗体－アマトキシンコンジュゲートの組合せを含む癌治療に使用するための組成物
EP3802601A1 (en) Trimeric polypeptide complexes and uses thereof
CN113811329A (zh) 抗pd-1抗体和其用途
CN116438198A (zh) 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体
US20250276077A1 (en) Epha2 antibodies
Bajic Treating colorectal cancer by targeting the carcinoembryonic antigen with immunocytokines and bispecific antibodies
HK40066344A (zh) Ox40/pd-l1双特异性抗体
HK40066344B (zh) Ox40/pd-l1双特异性抗体
HK40003232A (en) Novel bispecific polypeptides against cd137
HK40018012A (en) Compounds and methods for tumour-specific cell depletion

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003232

Country of ref document: HK